Center for Drug Discovery, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 United States.
Department of Chemistry, Rice University, 6100 Main Street, Houston, Texas 77005 United States.
ACS Comb Sci. 2020 Dec 14;22(12):833-843. doi: 10.1021/acscombsci.0c00144. Epub 2020 Oct 19.
Peptide drug discovery has shown a resurgence since 2000, bringing 28 non-insulin therapeutics to the market compared to 56 since its first peptide drug, insulin, in 1923. While the main method of discovery has been biological display-phage, mRNA, and ribosome-the synthetic limitations of biological systems has restricted the depth of exploration of peptide chemical space. In contrast, DNA-encoded chemistry offers the synergy of large numbers and ribosome-independent synthetic flexibility for the fast and deeper exploration of the same space. Hence, as a bridge to building DNA-encoded chemical libraries (DECLs) of peptides, we have developed substrate-tolerant amide coupling reaction conditions for amino acid monomers, performed a coupling screen to illustrate such tolerance, developed protecting group strategies for relevant amino acids and reported the limitations thereof, developed a strategy for the coupling of α,α-disubstituted alkenyl amino acids relevant to all-hydrocarbon stapled peptide drug discovery, developed reaction conditions for the coupling of tripeptides likely to be used in DECL builds, and synthesized a fully deprotected DNA-decamer conjugate to illustrate the potency of the developed methodology for on-DNA peptide synthesis.
自 2000 年以来,肽类药物的发现呈现出复苏的态势,共有 28 种非胰岛素治疗药物上市,而自 1923 年首个肽类药物胰岛素上市以来,共有 56 种。虽然主要的发现方法是生物展示——噬菌体、mRNA 和核糖体——但生物系统的合成限制限制了对肽类化学空间的深入探索。相比之下,DNA 编码化学为快速而深入地探索相同的空间提供了大量的、核糖体独立的合成灵活性的协同作用。因此,作为构建 DNA 编码化学文库 (DECL) 的桥梁,我们开发了对氨基酸单体具有耐受性的酰胺偶联反应条件,进行了偶联筛选以说明这种耐受性,为相关氨基酸开发了保护基策略并报告了其局限性,开发了一种用于偶联与全烃 stapled 肽药物发现相关的α,α-二取代烯基氨基酸的策略,开发了用于 DECL 构建的三肽偶联的反应条件,并合成了完全脱保护的 DNA-十聚体缀合物,以说明开发的方法在 DNA 上肽合成中的效力。